



Gpihpb1

Data Sheet

Catalog Number:	RA25016	Host:	Rabbit
Product Type:	Affinity Purified	Species Reactivity:	Mouse, Rat
Immunogen Sequence:	A synthetic peptide within an internal region [residues 100-200] of the mouse GPI-anchored HDL-binding protein 1 protein. [Swiss-Prot# Q9D1N2].	Format:	Liquid -PBS with .05% Sodium Azide. Concentration of 1 mg/ml.
Applications:	Western blot-.2 ug/ml. Immunohistochemistry-1ug/ml (paraffin fixed tissue only)		

*Dilutions listed as a recommendation. Optimal dilution should be determined by investigator.

Storage: Store frozen. Aliquot as undiluted antisera and immediately place at -20°C. Antisera may have become trapped in top of vial during shipping. Centrifugation of vial is recommended before opening. Stable for at least 6 months at -20°C. Repeated freeze/thaw cycles compromise the integrity of the antiserum.


Application Notes

Reference: Beigneux, AP, et al. Cell Metabolism. 5(4): 279-291 (2007)

Description/Data:

GPI-anchored HDL-binding protein 1 (Gpihpb1) is a novel protein that may be involved in the regulation of the delivery of fats to cells for energy and storage. Digested fats travel to the small intestine, where they are packaged into chylomicrons (particles filled with triglycerides). Chylomicrons then travel through the bloodstream and deliver triglycerides to tissues that are hungry for fuel or to adipose tissue for energy storage. Triglycerides are broken down or hydrolyzed by the enzyme lipoprotein lipase (LpL). The triglyceride breakdown products are then taken up and used by cells. Gpihpb1 is the molecule in capillaries that facilitates the capture of chylomicrons and facilitates the interaction with LpL. It has been shown that fats in the bloodstream are not readily metabolized in the absence of GPIHBP1.

Image: Detection of Gpihpb1 in transfected lysate (Lane 1). An empty vector lysate was used as a negative control (Lane 2).



FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. -V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com